Selecta Biosciences (SELB) Misses Q3 EPS by 9c; Reports Cash and Cash Equivalents of $140.0M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Selecta Biosciences (SELB) Announces Top Line Data from Phase I SEL-399 AAV Empty Capsid Study, Highlighting Potential Benefits of ImmTOR in Gene Therapy
November 8, 2021 8:13 AM ESTSelecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced top-line results from a joint Selecta and AskBio Phase I randomized, placebo controlled, double blind, dose-escalation study to evaluate the potential of its ImmTOR platform in mitigating the formation of neutralizing antibodies against an adeno-associated viral serotype 8 (AAV8) serotype capsid used in gene therapies. At day 30, in those subjects administered a single 0.3 mg/kg dose of ImmTOR, Selecta observed a median anti-AAV8 neutralizing antibody titer of 1:5, a 250-fold lower level... More
